Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2011

View Archived Issues

Microbicide vaginal gel containing C2F5/C4E10/C2G12 MAbs for HIV-1 is safe in phase I trial

Renovo discloses exploratory analysis data on Juvista and announces restructuring

Gemtuzumab ozogamicin improves survival of patients with AML and favorable cytogenetics

Lilly submits application seeking additional indication for Zyprexa in Japan

European orphan drug status for Talecris' human plasmin in acute peripheral arterial occlusion

Multiple-antigen MVA/DNA HIV vaccine regimen is safe and immunogenic in phase I trial

EMA accepts Insmed's pediatric investigation plan for Arikace

Vanda Pharma's tasimelteon receives European orphan drug status in N24HSWD

FDA accepts for review dapagliflozin NDA for type 2 diabetes

Inovio begins phase II VGX-3100 vaccine program for cervical dysplasia caused by HPV

New lysophospholipid S1P1 receptor agonists reported by Bristol-Myers Squibb

Amgen acquires BioVex

Primary endpoint met in phase II trial of inhaled bimosiamose in COPD

Amira Pharma describes salts of a prostanoid DP2 receptor antagonist

Downregulated FGFR-3 expression predicts poor outcome of pancreatic islet cell tumors

Concert Pharma prepares new deuterated PGI2 receptor agonists

GSK patents new activators of Toll-like receptor 7 and/or 8

Novel inhibitors of HCV RNA replication designed at Tibotec

New topiramate label warns for risk of oral clefts in newborns

AstraZeneca and Galderma to develop dermatological therapies

Novartis Diagnostics to market Grifols' immunohematology diagnostics in U.S.

Kaletra label changed due to health risks in premature babies

FDA committee recommends approval of QAB-149 to treat airflow obstruction in COPD

Amsterdam Molecular Therapeutics receives grant to develop AMT-080 for Duchenne's muscular dystrophy

Phosphorylated forkhead box protein O1 has prognostic value in pancreatic ductal adenocarcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...